Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.
Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
UK Researchers Show Cytotoxic T-Cell Level Predicts Melanoma Immunotherapy Response
A Science Immunology paper details how patients with more cytotoxic effector T cells in peripheral blood at baseline respond better to checkpoint inhibitors.
Sophia Genetics, Spanish Lung Cancer Group Team up to Predict Lung Cancer Treatment Response
The firm and cancer centers will use radiomics, clinical, biologic, and genomics data to predict responses to neoadjuvant nivolumab plus chemo in NSCLC.